Last reviewed · How we verify

NCT05625984

Study With Fascigel

Completed NA Last updated 7 February 2024
What this trial tests

NA trial testing Fascigel in Back Pain in 55 participants. Completed in 13 November 2023.

Timeline
24 October 2022
Primary endpoint
13 November 2023
13 November 2023

Quick facts

Lead sponsorContipro Pharma a.s.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment55
Start date24 October 2022
Primary completion13 November 2023
Estimated completion13 November 2023
Sites3 locations across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Contipro Pharma a.s. — full company profile →

Who can join

18 and older, any sex, with Back Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution. The device intended use is to help treat back pain by lubricating fascia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Back Pain

Currently open trials in the same condition.

Other Contipro Pharma a.s. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05625984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing